PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.71%
G&A growth less than half of TRAW's 61301.60%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
-38.54%
Other expenses reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
25.41%
Operating expenses growth less than half of TRAW's 75603.42%. David Dodd would verify sustainability.
25.41%
Total costs growth while TRAW reduces costs. John Neff would investigate differences.
-10.64%
Interest expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
353.66%
Other expenses growth less than half of TRAW's 1151.26%. David Dodd would verify if advantage is sustainable.
100.00%
Pre-tax income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-610.74%
Tax expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
610.74%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
609.26%
EPS growth while TRAW declines. John Neff would investigate advantages.
609.26%
Diluted EPS growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.